Screener
Travere Therapeutics, Inc. TVTX Q2 2026 earnings
Reported August 4, 2026 · After market close
Revenue$169.6MBeat by $12.3M
EPS-$0.37Miss by $0.24
Revenue estimate$157.3M
EPS estimate-$0.13
“Our performance reflects the strength of the company we are building and the disciplined execution of our teams as we continue to deliver on our strategy. During the quarter, we made meaningful progress across each of our strategic growth pillars, driving continued commercial momentum for FILSPARI, including a promising early launch in FSGS and continued strength in IgA nephropathy, as well as advancing our pegtibatinase program toward its pivotal Phase 3 readout and expanding our rare kidney disease pipeline through the addition of civorebrutinib. Together, these strengthen the durability of our growth profile, diversify our pipeline and reinforce our commitment to delivering meaningful new therapies for people living with rare diseases.”
Next report
Nov 2, 2026 (Today)Revenue estimate$195.3M
EPS estimate-$0.10
Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Travere Therapeutics, Inc. report Q2 2026 earnings?
- Travere Therapeutics, Inc. (TVTX) reported Q2 2026 earnings on August 4, 2026 after market close.
- What were Travere Therapeutics, Inc.'s Q2 2026 revenue and EPS?
- Travere Therapeutics, Inc. reported revenue of $169.6M and eps of $-0.37 for Q2 2026.
- Did Travere Therapeutics, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $157.3M by $12.3M. EPS missed the consensus estimate of $-0.13 by $0.24.
- How did Travere Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 48.2% from $114.4M a year earlier and eps declined 164.3% from $-0.14.
- Where can I find Travere Therapeutics, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001438533-26-000062) and the 10-Q periodic report (0001438533-26-000063) directly on SEC EDGAR. The filing index links above go to sec.gov.
